TB-500

TB-500 (10mg) — Thymosin Beta-4 Actin-Binding Research Peptide

TB-500 is a synthetic research peptide based on thymosin beta-4, a naturally occurring 43-amino-acid protein found in almost every mammalian cell and originally isolated from thymus tissue. Strictly, TB-500 refers to the N-terminally acetylated 17-23 segment of thymosin beta-4 (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln), the short sequence that carries the protein's actin-binding activity, although the name is also used in research supply for full-length thymosin beta-4. It is often written as TB 500, TB500 or tb500 peptide, and sometimes described as a thymosin beta-4 fragment or Tβ4 fragment.

TB-500 is studied principally for soft-tissue repair, angiogenesis and modulation of inflammation, with secondary lines of research in cardiac and corneal injury models. At the molecular level it acts by binding monomeric G-actin, the building block of the cytoskeleton, which regulates actin polymerisation and allows cells to reorganise, migrate and divide during tissue repair.

Omega Peptides Australia supplies TB-500 as a high-purity (≥99% HPLC) COA-verified lyophilised powder in a sealed sterile 10mg vial. Orders placed before 12pm are dispatched the same day from within Australia, and the Certificate of Analysis for each batch is published in our COA library. Researchers looking to buy TB-500 in Australia get verified purity, batch-level documentation and domestic stock with no customs delays.

Key research areas

• Wound and dermal repair Thymosin beta-4 has been studied in full-thickness wound, burn and impaired-healing models, and full-length thymosin beta-4 has progressed through Phase 2 clinical programmes in chronic dermal wounds. The proposed mechanism is increased keratinocyte and fibroblast migration into the wound bed, together with greater collagen deposition and faster re-epithelialisation.
• Angiogenesis Endothelial cell migration, tube formation and new capillary growth have been examined in vitro and in rodent models. Thymosin beta-4 is thought to promote vessel formation by driving endothelial cell motility through actin regulation and by increasing the expression of pro-angiogenic factors including VEGF.
• Inflammation Preclinical studies have investigated the peptide's capacity to reduce inflammatory signalling in injured tissue. Reduced NF-κB activation and lower levels of inflammatory cytokines have been reported, which is proposed to explain the reduced scarring and faster resolution seen in some repair models.
• Cardiac research Rodent studies of myocardial infarction have investigated thymosin beta-4 for cardiomyocyte survival and the activation of epicardial progenitor cells, with reports of new vessel formation within heart muscle. The mechanism has been linked to integrin-linked kinase and Akt survival signalling.
• Corneal and ocular repair Thymosin beta-4 has been studied in corneal wound models and in clinical programmes for dry eye and neurotrophic keratopathy, where it is proposed to promote epithelial cell migration and reduce inflammation on the ocular surface.
• Tendon, ligament and muscle models Because of its role in cell migration, TB-500 is frequently studied alongside BPC-157 in connective-tissue injury models. Research in this area looks at flexibility of healed tissue, muscle fibre regeneration and the speed of cellular infiltration into the injury site.

How TB-500 works

Thymosin beta-4 is the main G-actin sequestering protein in the cell. By binding actin monomers it controls how much free actin is available for polymerisation, and this regulation of the cytoskeleton is what allows cells to change shape, move and divide. The 17-23 region of the protein, Leu-Lys-Lys-Thr-Glu-Thr-Gln, is the actin-binding motif, and TB-500 reproduces this segment with an acetyl group on the N-terminus. In vitro and rodent studies suggest the downstream effects include faster migration of endothelial cells, keratinocytes and fibroblasts into injured tissue, increased angiogenesis, and reduced inflammatory signalling and apoptosis.

Full-length thymosin beta-4 and the short TB-500 fragment are not identical. The full protein also carries an N-terminal tetrapeptide, Ac-SDKP, which is cleaved off in the body and has been studied separately for anti-fibrotic activity; the seven-residue fragment does not include this region. An analytical study published in 2012 identified the acetylated 17-23 fragment in a product sold as TB-500, which is why the name is applied to the fragment, while some research-grade material is full-length protein. The batch COA identifies the exact molecular weight of the material supplied. Thymosin beta-4 has a short plasma half-life, but its cytoskeletal effects are studied over days to weeks. Compared with BPC-157, which signals mainly through growth-factor and nitric-oxide pathways, TB-500 works through the actin cytoskeleton, which is why the two are so often paired.

Specifications

Available sizes and pricing

TB-500 is supplied in a single 10mg vial. Each vial is labelled with its batch number so the material can be matched to its Certificate of Analysis. If your work also involves BPC-157, the BPC-157 + TB-500 blend provides 5mg of each in one vial, and the multi-peptide KLOW blend includes 10mg of TB-500 alongside GHK-Cu, BPC-157 and KPV at a lower cost per mg.

• 10mg vial — $99.99 (about $10.00 per mg)

Quality and COA verification

Every batch of TB-500 is independently tested by Janoshik Analytical. HPLC confirms purity, and mass spectrometry confirms the identity of the peptide by matching its measured mass to the expected molecular weight, which also tells you whether the batch is the 17-23 fragment or full-length thymosin beta-4. A Certificate of Analysis is issued for every batch and published in our COA library, where you can check the batch number printed on your vial. The peptide is lyophilised for long-term stability, sealed in a sterile vial, and packed in protective packaging for domestic transit. Because our stock is held in Australia, vials are not subjected to weeks of international shipping or customs holds.

Frequently bought together

• BPC-157 (10mg) — $99.99, the growth-factor-pathway repair peptide most often studied alongside TB-500
• BPC-157 + TB-500 Blend (10mg) — $119.99, 5mg of each peptide pre-combined in one vial
• KLOW (80mg) — $149.99, a four-peptide blend of GHK-Cu, BPC-157, TB-500 and KPV
• Bacteriostatic Water (10mL) — $29.99, for reconstituting the lyophilised powder

Research guides

• BPC-157 vs TB-500
• BPC-157 research guide
• How to store lyophilised peptides
• COA testing explained
• Peptide reconstitution calculator
• Certificates of Analysis library

Frequently asked questions

What is TB500?
TB500 is simply TB-500 written without the hyphen, and both refer to the same synthetic research peptide derived from thymosin beta-4. The name was originally a product code rather than a chemical name, which is why you will see it spelled TB500, TB 500 or TB-500 in the literature and in search results. It is supplied here as a 10mg lyophilised powder for laboratory research.

What is TB-500?
TB-500 is a synthetic peptide that reproduces the actin-binding region of thymosin beta-4, a 43-amino-acid protein present in nearly all mammalian cells. The defined fragment is the acetylated 17-23 sequence, Ac-LKKTETQ, with a molecular weight of about 889 g/mol, although the term is also used for full-length thymosin beta-4 in research supply. It is studied in wound healing, angiogenesis, inflammation and cardiac injury models.

What is TB-500 also known as?
It is also written as TB 500, TB500, tb500 peptide and TB-500 peptide. Because it is derived from thymosin beta-4, it is described as a thymosin beta-4 fragment, Tβ4 fragment or thymosin beta-4 17-23, and full-length material is sometimes labelled thymosin beta-4 or Tβ4. In online discussion the BPC-157 and TB-500 pairing is informally called the Wolverine stack.

How does TB-500 work?
Thymosin beta-4 is the cell's main actin-sequestering protein. TB-500 carries the Leu-Lys-Lys-Thr-Glu-Thr-Gln motif that binds G-actin, and by regulating actin polymerisation it influences how readily cells reorganise their cytoskeleton, migrate and divide. In vitro and rodent studies link this to faster migration of endothelial cells, keratinocytes and fibroblasts into injured tissue, increased angiogenesis, reduced NF-κB-driven inflammation, and improved cell survival through Akt signalling.

What does the research show about TB-500?
Preclinical models have reported faster closure of dermal wounds, increased new vessel formation, reduced inflammation and scarring, improved corneal epithelial repair, and cardiomyocyte survival after experimental infarction. Full-length thymosin beta-4 has been assessed in Phase 2 clinical programmes for chronic dermal wounds and for dry eye and neurotrophic keratopathy. The short TB-500 fragment itself has far less published data and remains an investigational research compound.

Can I buy TB-500 at Chemist Warehouse or a pharmacy in Australia?
No. There is no TB-500 or thymosin beta-4 product registered on the Australian Register of Therapeutic Goods, so Chemist Warehouse, Priceline and other retail pharmacies do not sell it. The research-grade lyophilised peptide supplied by Omega Peptides Australia is a laboratory reagent for in-vitro use, not a pharmacy product.

Can Australian compounding pharmacies supply TB-500?
Not as a stock item. With no approved product available, an unapproved peptide can only be compounded extemporaneously for an individual patient on a valid prescription, and the TGA has reminded pharmacies of their obligations when handling unapproved peptides. Omega Peptides Australia is not a pharmacy and does not compound medicines. We supply the lyophilised research compound with a batch COA, strictly for laboratory research.

How do you reconstitute TB-500?
Use bacteriostatic water. Swab the stopper, then add the chosen volume of water slowly down the inside wall of the vial so it runs onto the powder rather than jetting into it. Swirl gently until the solution is clear, do not shake, because agitation can damage the peptide. Label the vial with the date and concentration, refrigerate at 2–8°C and use within 28 days. Our reconstitution calculator handles the concentration maths.

How should TB-500 be stored?
Keep the lyophilised vial sealed and protected from light and moisture. Short-term storage at 2–8°C is fine; for long-term storage keep it at −20°C and avoid repeated freeze-thaw cycles. After reconstitution, store the solution refrigerated at 2–8°C and use it within 28 days. Allow a cold vial to reach room temperature before opening it, so that condensation does not form on the powder.

Where can I buy TB-500 in Australia?
Directly from Omega Peptides Australia. Stock is held domestically, orders placed before 12pm are dispatched the same day, and every batch is tested by Janoshik Analytical with the certificate published in our COA library. TB-500 can be ordered on this page or browsed with the rest of our research peptides in Australia, including BPC-157, the BPC-157 + TB-500 blend and the KLOW and GLOW multi-peptide blends.

What does TB-500 cost in Australia?
TB-500 10mg is $99.99 per vial, or about $10.00 per mg. The BPC-157 + TB-500 blend, containing 5mg of each peptide, is $119.99 per 10mg vial. The KLOW blend (80mg, including 10mg of TB-500) is $149.99, which lowers the overall cost per mg for laboratories that want all four peptides. Bacteriostatic water is sold separately at $29.99 for 10mL or $14.99 for 3mL.

How do I get TB-500 online in Australia?
Add the 10mg vial to your cart, add bacteriostatic water if required, and complete checkout. Orders ship from within Australia with tracked domestic delivery and discreet, unbranded packaging. Orders placed before 12pm on a business day are dispatched the same day and later orders leave the next business day. A tracking number is emailed once the parcel has been scanned by the carrier.

Is TB-500 legal in Australia?
Omega Peptides Australia supplies TB-500 strictly for lawful in-vitro laboratory research. It is not approved by the TGA for human or veterinary use and is not sold as a medicine or supplement. Purchasers are responsible for ensuring their intended use complies with all applicable laws.

How does TB-500 differ from BPC-157, and why are they studied together?
TB-500 works through the actin cytoskeleton, regulating how cells migrate and reorganise, while BPC-157 works mainly through growth-factor and nitric-oxide signalling that promotes angiogenesis and collagen production. Because they target different steps of the same repair process, researchers often study them together or in a single blended vial. Our BPC-157 vs TB-500 guide compares their structures, mechanisms and research histories in more detail.

⚠ For in-vitro research and laboratory use only. Not for human or veterinary use.